LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announc
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2021 Results - Earnings Call Transcript

Verona Pharma: Q4 Earnings Insights

01:10pm, Thursday, 03'rd Mar 2022 Benzinga
Verona Pharma (NASDAQ: VRNA ) reported its Q4 earnings results on Thursday, March 3, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Verona Pharma beat estimated earnings by 16.67%, reporting … Full story available on Benzinga.com

Verona Pharma ADR Earnings Beat, Revenue Inline In Q1 By Investing.com

11:37am, Thursday, 03'rd Mar 2022 Investing.com
Verona Pharma ADR Earnings Beat, Revenue Inline In Q1

Verona Pharma GAAP EPS of -$0.05 beats by $0.30

07:52am, Thursday, 03'rd Mar 2022 Seeking Alpha
Verona Pharma press release (VRNA): Q4 GAAP EPS of -$0.05 beats by $0.30.Cash and cash equivalents at December 31, 2021, were $148.4 M (December 31, 2020: $188.0M)
Phase 3 ENHANCE program on track to report top-line COPD data in 2022
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is being developed as a maintenance treatment for chronic obstructive respiratory disease. The stock is
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma (NASDAQ:VRNA) had its price objective hoisted by Canaccord Genuity from $18.00 to $23.00 in a report released on Friday morning, Price Targets.com reports. Canaccord Genuity currently has a buy rating on the stock. A number of other brokerages have also recently weighed in on VRNA. Zacks Investment Research cut shares of Verona Pharma []
Verona Pharma (NASDAQ:VRNA) had its price target hoisted by Canaccord Genuity from $18.00 to $23.00 in a research report released on Friday, Analyst Price Targets reports. Canaccord Genuity currently has a buy rating on the stock. Other equities analysts also recently issued reports about the stock. HC Wainwright began coverage on shares of Verona Pharma []
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE